Filing Flows › 20/20 Biolabs (AIDX) › Q2 2026 › vs Q1 2026
20/20 Biolabs (AIDX) Q2 2026 vs Q1 2026 (quarter over quarter)
20/20 Biolabs's revenue rose $377K (+107%) from $353K in Q1 2026 to $731K in Q2 2026. The biggest changes: OneTest +$386K (+124%); BioCheck +$13K (+61%).
20/20 Biolabs, Q2 2026: revenue $731K (+36% year over year), operating margin -170.3%, net loss $1.5M, operating cash flow −$605K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| OneTest | $696K | $310K | $386K | +124% |
| BioCheck | $35K | $22K | $13K | +61% |
| Revenue | $731K | $353K | $377K | +107% |
| Net loss | $1.5M | $2.2M | −$668K | -31% |
| Costs & expenses | $2.2M | $2.5M | −$291K | -12% |
| Operating costs | $2.0M | $1.8M | $178K | +10% |
| Interest & other, net | $262K | $731K | −$469K | -64% |
| Cost of revenue | $426K | $290K | $135K | +47% |
| Research & development | $258K | $153K | $104K | +68% |
| SG&A | $1.3M | $1.4M | −$61K | -5% |
| Operating cash sources | $1.5M | $2.2M | −$668K | -31% |
| Depreciation & amortization | $12K | $12K | −$2 | 0% |
| Share-based compensation | $371K | $128K | $243K | +189% |
| Working capital & other | $517K | $745K | −$228K | -31% |
| Cash used in operations | $605K | $1.3M | −$684K | -53% |
| Net loss absorbed | $1.5M | $2.2M | −$668K | -31% |
Questions
How much did 20/20 Biolabs's revenue grow quarter over quarter in Q2 2026?
20/20 Biolabs's revenue rose $377K (+107%) from $353K in Q1 2026 to $731K in Q2 2026.
What drove 20/20 Biolabs's revenue change in Q2 2026?
OneTest +$386K (+124%); BioCheck +$13K (+61%).